



HEALTH MANAGEMENT INTERNATIONAL LTD

(Incorporated in the Republic of Singapore)

(Company Registration No. 199805241E)

**THE PROPOSED INCREASE OF THE COMPANY'S OWNERSHIP IN 48.9%-OWNED
MAHKOTA MEDICAL CENTRE AND 60.8%-OWNED REGENCY SPECIALIST HOSPITAL TO
100% EACH AND THE PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS
ISSUE**

**RECEIPT OF APPROVAL IN-PRINCIPLE FROM THE SINGAPORE EXCHANGE
SECURITIES TRADING LIMITED**

Introduction

The Board of Directors (the **"Board"**) of Health Management International Ltd (the **"Company"** and together with its subsidiaries, the **"Group"**) refers to its announcement dated 11 November 2016 (the **"Announcement"**) in relation to:

- (a) the proposed increase of the Company's ownership in 48.9%-owned Mahkota Medical Centre and 60.8%-owned Regency Specialist Hospital to 100% each (the **"Acquisition"**);
- (b) as part of the Acquisition, the proposed acquisition of shares in Senipuri Emas Sdn. Bhd. and 2M Medical Consultants Pte. Ltd., and acceptance of an assignment of non interest-bearing shareholder's loans in 2M Medical Consultants Pte. Ltd., from Dr. Cheah Way Mun (the **"CWM Acquisition"**); and
- (c) the proposed Rights Issue.

Capitalised terms used herein, unless otherwise defined, shall bear the same meanings given to them in the Announcement.

Receipt of Approval In-Principle

Further to the Announcement, the Board is pleased to announce that the Company has, on 23 January 2017, received the approval in-principle from the Singapore Exchange Securities Trading Limited (the **"SGX-ST"**) for the listing of and quotation for the 199,822,890 Consideration Shares and up to 32,376,443 Rights Shares on the Main Board of the SGX-ST, subject to the following conditions:

- (a) compliance with the SGX-ST's listing requirements;
- (b) shareholders' approval for the Acquisition, the CWM Acquisition, and the Rights Issue;

- (c) a written undertaking from the Company that it will comply with Listing Rule 803;
- (d) a written undertaking from the Company that it will comply with Listing Rules 704(30), 815 and 1207(20) in relation to the use of the proceeds from the Rights Issue and where proceeds are to be used for working capital purposes, the Company will disclose a breakdown with specific details on the use of proceeds for working capital in the Company's announcements on use of proceeds and in the annual report;
- (e) a written undertaking from the Company that it will comply with Listing Rule 877(10) with regards to the allotment of any excess Rights Shares; and
- (f) a written confirmation from financial institution(s) as required under Listing Rule 877(9) that the undertaking shareholders who have given the irrevocable undertakings have sufficient financial resources to fulfill their obligations under the undertakings.

The approval in-principle granted by the SGX-ST is not to be taken as an indication of the merits of the Acquisition, the Rights Issue, the ordinary shares in the capital of the Company, the Consideration Shares, the Rights Shares, the Company and/or its subsidiaries.

A circular to the shareholders of the Company (the “**Shareholders**”) containing, *inter alia*, details of the Acquisition and the Rights Issue, and the notice of the extraordinary general meeting to be convened, will be despatched to the Shareholders in due course.

By Order of the Board of
Health Management International Ltd

Dr. Gan See Khem
Executive Chairman and Managing Director
23 January 2017, Singapore